At the time of writing, Adaptimmune Therapeutics Plc ADR [ADAP] stock is trading at $0.80, up 10.23%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ADAP shares have gain 8.45% over the last week, with a monthly amount drifted -10.64%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] stock has seen the most recent analyst activity on July 30, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $4. Previously, Scotiabank started tracking the stock with Sector Outperform rating on May 30, 2024, and set its price target to $3.15. On March 24, 2023, Bryan Garnier initiated with a Buy rating and assigned a price target of $3.60 on the stock. Guggenheim upgraded its rating to a Buy but stick to its price target of $5 on January 03, 2023. Mizuho upgraded its rating to a Buy but $9 remained the price target by the analyst firm on November 09, 2022. Barclays started tracking with a Underweight rating for this stock on May 28, 2021, and assigned it a price target of $4. In a note dated April 22, 2020, Mizuho initiated an Neutral rating and provided a target price of $3 on this stock.
For the past year, the stock price of Adaptimmune Therapeutics Plc ADR fluctuated between $0.42 and $2.05. Currently, Wall Street analysts expect the stock to reach $2.83 within the next 12 months. Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] shares were valued at $0.80 at the most recent close of the market. An investor can expect a potential return of 253.75% based on the average ADAP price forecast.
Analyzing the ADAP fundamentals
According to Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP], the company’s sales were 141.56M for trailing twelve months, which represents an 2394.41% jump. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.59%, Pretax Profit Margin comes in at -0.55%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -1.17 and Total Capital is -0.35. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7479 points at the first support level, and at 0.6960 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8358, and for the 2nd resistance point, it is at 0.8718.
Ratios To Look Out For
It is important to note that Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] has a current ratio of 3.09. Further, the Quick Ratio stands at 3.09, while the Cash Ratio is 2.58. Considering the valuation of this stock, the price to sales ratio is 1.44, the price to book ratio is 2.12.
Transactions by insiders
Recent insider trading involved Piccina Cintia, Chief Commercial Officer, that happened on Jun 18 ’24 when 24531.0 shares were sold. Chief Executive Officer, Rawcliffe Adrian completed a deal on Jan 17 ’24 to sell 30080.0 shares. Meanwhile, Chief Executive Officer Rawcliffe Adrian sold 9304.0 shares on Jan 16 ’24.
